Skip to Content

'
Anne S. Tsao, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Mesothelioma Program, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Thoracic Chemo-Radiation Program, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 432
Houston, TX 77030
Room Number: Faculty Center FC9.3002
Phone: 713-792-6363
Fax: 713-792-1220

Education & Training

N/A

Experience/Service

Academic Appointments

Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002-5/2010

Administrative Appointments/Responsibilities

Chair, Clinical Research Committee (CRC), The University of Texas MD Anderson Cancer Center, Houston, TX, 2010-2013
Associate Member, Institutional Review Board (IRB), The University of Texas MD Anderson Cancer Center, Houston, TX, 2010-2013

Other Appointments/Responsibilities

Coordinator Clinical Protocol, University of Chicago, Dept of Rheumatology, Chicato, IL, 1997-1999

Institutional Committee Activities

Chair, MDACC Clinical Research Committee (CRC), 2010-2013
Member, MDACC Clinical Research Committee (CRC), 6/2008-present

Professional Memberships

NCCN Guidelines - Mesothelioma Committee
Member, 2009
RTOG
Executive Committe Member, 2010-present
SWOG Lung Committee
Executive Committe, Member, 2007-present
SWOG Mesothelioma Steering Committee
Member, 2008-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Sejpal S, Komaki R, Tsao A, Chang JY, Liao Z, Wei X, Allen PK, Lu C, Gillin M, Cox JD. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer 117(13):3004-13, 7/2011. e-Pub 1/2011. PMID: 21264827.
2. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The Battle Trial: Personalizing Therapy for Lung Cancer. Cancer Discovery. e-Pub 4/2011.
3. Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, Gillin M, Mohan R, Cox JD. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. e-Pub 3/22/2011. PMID: 21437893.
4. Tsao AS, Garland L, Redman M, Kernstine K, Gandara D, Marom EM. A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. J Thorac Oncol 6(3):598-601, 3/2011. PMID: 21270668.
5. Garland L, Flores R, Tsao A. Individualizing mesothelioma treatment: small steps into a brighter future. Clin Lung Cancer 11(6):371-3, 11/1/2010. PMID: 21062727.
6. Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, Roder J, Tsypin M, Herbst RS, Tsao AS, Tran HT, Dang TP. VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 69(3):337-40, 9/2010. e-Pub 12/2009. PMCID: PMC2891357.
7. Tsao AS, Roth J, Herbst R. Future directions in multimodality therapy for III A NSCLC: Intergroup Trial 0139. Nature Reviews Clinical Oncology 7(1):10-12, 1/2010. PMID: 20029443.
8. Dayyani F, Etzel C, Liu M, Ho Chung-Han, Lippman S, Tsao A. Meta-anlysis of the impact of human papilomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head and Neck Oncology 2(15), 2010.
9. Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM, Hong WK, Papadimitrakopoulou V. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) 2(11):931-941, 11/2009. PMID: 19892663.
10. McAleer MF, Tsao AS, Liao Z. Radiotherapy in malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 75(2):326-37, 10/1/2009. PMID: 19735859.
11. Salmon S, Chen H, Chen S, Herbst R, Tsao A, Tran H, Sandler A, Billheimer D, Shyr Y, Lee JW, Massion P, Brahmer J, Schiller J, Carbone D, Dang TP. Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. J Thorac Oncol 4(6):689-696, 6/2009. PMID: 19404214.
12. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant Pleural Mesothelioma. J Clin Oncol 27(12):2081-90, 4/20/2009. e-Pub 3/2/2009. PMID: 19255316.
13. Tsao AS, Mehran R, Roth JA. Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma. Clin Lung Cancer 10(1):36-41, 1/2009. PMID: 19289370.
14. Ivanova AV, Ivanov SV, Prudkin L, Nonaka D, Liu Z, Tsao A, Wistuba I, Roth J, Pass HI. Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. Mol Cancer 8:91, 2009. e-Pub 10/2009. PMCID: PMC2776015.
15. Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma BAC subtype predict response to erlotinib. J Clin Oncol 26(9):1472-1478, 3/20/2008. PMID: 18349398.
16. Rice DC, Stevens CW, Correa AM, Vaporciyan AA, Tsao A, Forster KM, Walsh GL, Swisher SG, Hofstetter WL, Mehran RJ, Roth JA, Liao Z, Smythe WR. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 84(5):1685 - 1692, 11/2007. PMID: 17954086.
17. Carbone M, Albelda S, Boaddus V, Flores R, Hillerdal G, Jaurand M, Kjaerheim K, Pass H, Robinson B, Tsao A. Eighth International Mesothelioma Interest Group. Oncogene 26(49):1685-1692, 10/2007. PMID: 17496929.
18. Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 6(7):1962-1970, 7/2007. PMID: 17620427.
19. Tsao AS, Ensley J, Hong WK,El-Naggar AK, Papadimitrakopoulou V. Successful Biochemoprevention in a patient with multiple aerodigestive malignancies. International Journal of Cancer Prevention 2(4):297-300, 5/2007.
20. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol 24(25):4163-9, 9/1/2006. PMID: 16943532.
21. Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 106(11):2428-36, 6/1/2006. PMID: 16634096.
22. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 7(5):326-331, 3/2006. PMID: 16640804.
23. Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, Spitz M, Hong WK, Gazdar A, Wistuba I. Clinical-Pathological Characteristics of the EGFR Gene Mutation in Non-small Cell Lung Cancer. J Thorac Oncol 1(3):231-239, 3/2006. PMID: 17409862.

Invited Articles
1. Tsao AS. Cetuximab combined with chemotherapy in NSCLC. Community Oncology 7(1):17-22, 1/2010. e-Pub 1/2010.
2. Tsao AS. Novel Therapies in metastatic HNSCC. Community Oncology 6(7):310-316, 7/2009.
3. Karp DD, Tsao AS, Kim ES. Nonsmall-cell lung cancer: chemoprevention studies. Semin Thorac Cardiovasc Surg 15(4):405-20, 10/2003. PMID: 14710383.
4. Tsao AS and Herbst R. Factors that determine response to EGFR inhibitors. Signal 4(4):4-9, 7/2003.
5. Tsao AS Kim ES. Salvage therapies for Non-small cell lung cancer. Oncology Special Edition 6:167-170, 7/2003.
6. Tsao AS, Garey JS, An K, Kim ES. Understanding and managing toxicities related to EGFR inhibitors. HEGFR in Oncology 1(1):8-10, 7/2003.
7. Tsao AS. STI-571 and CML. British Journal of Haematology. British Journal of Haematology 119:15-24, 10/2002.
8. Kim ES Tsao AS. Novel Therapeutics in Non-Small Cell Lung Cancer. Lung Cancer Updates 3(4):1-20, 2002.
9. Tsao AS Tsao KY. Silicon Pressure Applications in the Medical Field. Industrial Materials, Taiwan 121:113-126, 1997.
Other Articles
1. Tsao A. Mesothelioma. CCO in Practice. www.inPractice.com, 2011.
2. Tsao A, Lin-Chi C, Vogelzang N. Review, Systemic treatment approaches for malignant mesothelioma. Up to Date website, www.uptodate.com, www.uptodate.com, 2010.
3. Tsao A. Update on Mesothelioma. Global Resource for Advancing Cancer Education, http://cancergrace.org/lung/2010/06/05/comprehensive-review-of-mesothelioma/, 2010.

Abstracts
1. Saintigny P, Diao L, Wang J, Girard L, Lin S, Coombes K, Liu S, Lee JJ, Weinstein J, Fan YH, Tang XM, Kim ES, Herbst RS, Tsao A, Blumenschein GR, Mao L, Lippman SM, Minna J, Hong WK, Wistuba II, Heymach JV. A 5-gene signature (sig predicts clinical benefit from erlotinib in non-small cell lung cancer (NSCLC) patients (pts) harboring wild-type (wt) EGFR & KRAS. American Association of Clinical Research, 2011.
2. Riquelme, E, Suraokar M, Nunez M, Gazdar A, Byers L, Heymach J, Mehran R, Tsao A and Wistuba I. Copy number gainof c-myc locus is frequently observed in malignant pleural mesothelioma with epithelioid histology. American Association for Cancer Research, 2011.
3. Nunez M, Suraokar M, Behrens C, Woods DM, Lin H, Lee JJ, Mehran R, Franklin W, Tsao A, Wistuba I. Folate pathway in Malignant Pleural Mesothelioma (MPM): Novel therapeutic opportunities due to Folate Receptor alpha overexpression. American Association for Cancer Research, 2011.
4. Suraokar M, Corvalan A, Chow C, Gazdar A, Moran C, Raso G, Mehran R, Tsao A, Wistuba I. Integrating microRNA and mRNA expression profiles identified a small st of unique genes up-regulated in malignant pleural mesothelioma (MPM). American Association for Cancer Research (#e22111). e-Pub 5/2009.
5. Dayyani F, Etzel C, Ho CH, Lippman S, Tsao A. Meta-analysis of the impact of human papilloma virus on cancer risk and overall survival in head and neck squamous cell carcinoma. American Society of Clinical Oncology 27(15S), 5/2009.
6. Kim E, Herbst R, Lee J, Blumenschein G, Tsao A. Phase II randomized studyof biomarker-directed treatment for NSLCC: The BATTLE (Biomarker-Integrated Approaches of Trageted Therapy for Lung Cancer Elimination) clinical trial program. American Scoiety of Clinical Oncology 27(15S), 5/2009.
7. Tang X, Kim ES, Alden C, Gupta S, Tsao AN, Blumenschein G, Liu S, Heymach J, Stewart D, Mao L, Hicks M, Lippman S, Lee JJ, Herbst R, Hong WK, Wistuba II. Feasibility and adequacy of molecular biomarker analysis from core needle biopsies in lung cancer: toward personalized targeted therapy development. American Association for Cancer Research (#744). e-Pub 2009.
8. Tsao AS, Liu D, Lee JJ, Heymach J, Pisters K, Brewer H, Hong WK, Blumenschein G. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemo-naive patients with unresectable malignant pleural mesothelioma. World Lung Cancer Conference - International Association for the Study of Lung Cancer (#7101), 2009.
9. Tsao AS, Gil J, Rice D Swisher S, Lippman S, Pisters K, Blumenschein G, Hong WK, Mehran R. Phase I trial of neoadjuvant dasatinib in patients with resectable malignant pleural mesothelioma. World Lung Cancer Conference - International Association for the Study of Lung Cancer (#7107), 2009.
10. Mehran R, Gil J, Ride D, Swisher S, Lee JJ, Lippman S, Pisters, Blumenschein G, Hong WK, Tsao AS. Phase I trial of neoadjuvant dasatinib in patients with respectable malignant pleural mesothelioma. American Society of Clinical Oncology (#7580). e-Pub 2009.
11. Tam A, Kim E, Herbst R, Wistuba I, Lee JJ, alden C, Tsao A, Blumenschein G, Efrasmus J, Hichs M, hong WK, Gupta S. Safety and adequacy of image-guided small caliber core needle biopsy for evaluation of multiple molecular biomarkers. World Lung Cancer Conference - International Association for the Study of Lung Cancer, 2009.
12. Suraokar M, He D, Llansa N, Mendoza G, Woods D, Prudkin L, Wistuba I, Tsao A. High expression of epithelial to mesenchymal transition (EMT) markers in mesothelioma and possible therapeutic intervention using an N-cadherin antagonist. American Association for Cancer Research (#8067), 2008.
13. Salmon J, Dang T, Billheimer D, Roder H, Grigorieva J, Tsypin M, Herbst R, Tsao A, Tran H, Carbone DP. VeriStrat predicts survival in patients with non-small celllung cancer (NSCLC) treated with erlotinib and bevacizumab. American Society of Clinical Oncology (#8008), 2008.
14. Tsao AS, He DD, Saigal B, Liu S, Lee J, Bakkannagari S, Ordonez, N, Hong W, Wistube I, Johnson F. Activated Src kinase is expressed in malignant pleural mesothelioma tumors; dasatinib inhibition leads to cytotoxicity, cell cycle inhibition, and prevention of invasion and migration. American Societyof Clinical Oncology 25(18S) (#7713), 6/2007.
15. Kim E, Kies M, Glisson B, Tsao A, Ginsberg L, Holsinger F, Burke B, Truong M, Papadimitrakopoulou V, Lippman S. Final results of a phase II study of erlotinib,docetaxel, and cisplatin in patients with recurrent/mestastatic head and neck cancer. American Society of Clinical Oncology 25(18S) (#6013), 6/2007.
16. Tsao AS, He D, Saigal B, Bakkannagari S, Hong W, Wistuba I, Johnson F. Src kinase is a new therapeutic target in malignant mesothelioma. American Society of Clinical Oncology (#7713), 5/2007.
17. Bakkannagari S,Saigal B, He D, Wistuba I, Hong W, Jonson F, Tsao AS. Inhibition of Src kinase in mesothelioma cell lines leads to cytotoxicity, inhibition of migration, and decreased invasion. American Association for Cancer Research (#3795), 2006.
18. Kris M, Sandler A, Miller V, Zakowski M, Pao W, Tsao A, Patel J, Johnson B, Johnson D, Carbone D. EGFR and KRAS mutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a phase II multicenter trial. American Society of Clinical Oncology (#7029), 10/2005.

Book Chapters
1. Tsao AS. Chemoprevention of Head and Neck. In: Head and Neck Cancer. Ed(s) Weber R, Ang K, Glisson B. In Press.
2. McAleer M, Mehran R, Tsao AS. Malignan Pleural Mesothelioma. In: Lung Cancer: Prevention, Management, and Emerging Therapies. Ed(s) Stewart. In Press.
3. Tsao AS, Papadimitrakopoulou V, Herbst R. Small molecule tyrosine kinase inhibitors.Causes of Cancer and Targets for Treatment. In: Molecular Oncology. Ed(s) Gelmann E, Sawyers C. In Press.
4. Tsao AS Glisson B. Small cell lung cancer. In: Medical Oncology: A Comprehensive Review. Medical Oncology: A Comprehensive Review, 2006.
5. Tsao AS, Kantarjian HM, Talpaz M. Chapter 8: Signal transduction inhibitors: Imatinib Mesylate. In: Drug Advances, 18th. Ed(s) J Gray. Drug Advances, 179-204, 2003.

Letters to the Editor
1. Tsao AS, Talpaz M. Letter to the Editor: STI-571 causes hypopigmentation in the skin. Cancer 100(11):2487-2488, 6/2004.

Manuals, Teaching Aids, Other Teaching Publications
1. Tsao AS, Hong WK. Treatment of Lung Cancer. 18th. Ed(s) Beers, Porter, Jones, Kaplan, Berkwits. Merck Manual of Diagnosis and Therapy: Whitehouse Station, NJ, 2006.

Grant & Contract Support

Title: PRMRP
Funding Source: Department of Defense (DOD)
Role: Principal Investigator
Duration: 2010 - 2014
 
Title: PROSPECT Grant
Funding Source: Department of Defense (DOD)
Role: Project Leader
Principal Investigator: W. K. Hong
Duration: 6/1/2007 - 6/30/2012
 
Title: National Institute of Health K12 Clinician Investigator Award
Funding Source: NIH/NCI
Role: Recipient
Duration: 2004 - 2008
 
Title: Young Investigator Award
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 2003 - 2005

Last updated: 7/18/2011